Abstract
To test the behaviour of a mutant form of p53 in the presence and absence of wild–type p53 in vivo, we mated p53–deficient mice containing a p53 null allele to transgenic mice containing multiple copies of a mutant p53 gene (Val 135). Animals hemizygous for the endogenous wild–type p53 gene with the mutant transgene exhibited accelerated tumour development and an altered tumour spectrum compared to their non–transgenic counterparts. In contrast, transgenic and non–transgenic animals nullizygous for endogenous p53 developed tumours at the same rate. Thus, the mutant Val–135 p53 allele may act in vivo in a dominant negative manner in the presence of wild–type p53 but does not display gain of function activity in the absence of wild–type p53.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Mowat, M., Cheng, A., Kimura, N., Bernstein, A. & Benchimol, S. Rearrangements of the Cellular p53 gene In erythroleukemic cells transformed by Friend virus. Nature 314, 633–636 (1985).
Ben-David, Y. & Bernstein, A. Friend virus-induced erythroleukaemia and the multistage nature of cancer. Cell 66, 831–834 (1991).
Hollstein, M., Sidransky, D., Vogelstein, B. & Harris, C.C. p53 mutations in human cancers. Science 252, 49–53 (1991).
Greenblatt, M.S., Bennett, W.P., Hollstein, M. & Harris, C.C. Mutations in the p53 tumour suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855–4878 (1994).
Lane, D.P. p53 and human cancers. B. Med. Bull. 50, 582–599 (1994).
Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. & Cline, M.J. Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. natn. Acad. Scl. U.S.A. 84, 7716–7719 (1987).
Nigro, J.M. et al. Mutations in the p53 gene occur in diverse tumour types. Nature 342, 705–708 (1989).
Caron de Fromentel, C. & Soussi, T. TP53 tumour suppressor gene: A model for investigating human mutagenesis. Genes, Chrom. Cancer 4, 1–15 (1992).
Cho, Y., Gorina, S., Jeffrey, P.D. & Pavletich, N.P. Crystal structure of a p53 tumour suppressor-DNA complex: Understanding tumorigenic mutations. Science 265, 346–355 (1994).
Malkin, D. et al. Germline p53 mutations In a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233–1238 (1990).
Srivastava, S., Zou, Z., Pirollo, K., Blattner, W. & Chang, E.H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348, 747–749 (1990).
Malkin, D. p53 and the Li-Fraumeni Syndrome. Cancer Genet. Cytogenet. 66, 83–92 (1993).
Kuerbitz, S.J., Plunkett, B.S., Walsh, W.V. & Kastan, M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. natn. Acad. Sci. U.S.A. 89, 7491–7495 (1992).
Kastan, M.B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R.W. Participation of p53 protein in the Cellular response to DNA damage. Cancer Res. 51, 6304–6311 (1991).
Kastan, M.B. et al. A mammalian cell cyde checkpoint pathway utilizing p53 and GADD45 is affective in ataxia-telangiectasia. Cell 71, 587–597 (1992).
Yonish-Rouach, E. et al. Wild-type p53 Induces apoptosis of myeloid leukaemic cells that is inhibited by interieukin-6. Nature 352, 345–347 (1991).
Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849–852 (1993).
Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation-induced apoptosis In mouse thymocytes. Nature 362, 847–849 (1993).
Lee, J.M. & Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. natn. Acad. Sci. U.S.A. 90, 5742–5746 (1993).
Lowe, S.W., Ruley, H.E., Jacks, T. & Housman, D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74, 957–967 (1993).
Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. & Elledge, S.J. The p21 cdk-lnteractlng protein cip1 Is a potent Inhibitor of G1 cyclin-dependent kinases. Cell 75, 805–816 (1993).
El-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumour suppression. Cell 75, 817–825 (1993).
Michalovitz, D., Halevy, O. & Oren, M., Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62, 671–680 (1990).
Martinez, J., Georgoff, I., Martinez, J. & Levine, A.J. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5, 151–159 (1991).
Farmer, G. et al. Wild-type p53 activates transcription in vitro. Nature 358, 83–86 (1992).
Kern, S.E. et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827–830 (1992).
Milner, J., Medcalf, E.A. & Cook, A.C. Tumour suppressor p53: Analysis of wild-type and mutant p53 complexes. Molec. Cell. Biol. 11, 12–19 (1991).
Milner, J. & Medcalf, E.A. Cotranslation of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell 65, 765–774 (1991).
Wolf, D., Harris, N. & Rotter, V. Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell 38, 119–126 (1984).
Shaulsky, G., Goldfinger, N. & Rotter, V. Alterations in tumour development in vivo mediated by expression of wild-type or mutant p53 proteins. Cancer Res. 51, 5232–5237 (1991).
Dittmer, D. et al Gain of function mutations in p53. Nature Genet. 4, 42–46 (1993).
Halevy, O., Michalovitz, D. & Oren, M. Different tumour-derived p53 mutants exhibit distinct biological activities. Science 250, 113–116 (1990).
Hinds, P.W. et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes. Cell Growth Differ. 1, 571–580 (1990).
Chin, K.-V., Ueda, K., Pastan, I. & Gottesman, M.M. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science 255, 459–462 (1992).
Deb, S., Jackson, C.T., Subler, M.A. & Martin, D.W. Modulation of cellular and viral promoters by mutant p53 proteins found in tumour cells. J. Virol. 66, 6164–6170 (1992).
Lavigueur, A. et al. High incidence of lung, bone, and lymphold tumours In transgenic mice overexpressing mutant alleles of the p53 oncogene. Molec. Cell. Biol. 9, 3982–3991 (1989).
Donehower, L.A. et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215–221 (1992).
Hinds, P., Finlay, C. & Levine, A.J. Mutation is required to activate the p53 gene for cooperation with the ras oncogne and transformation. J. Virol. 63, 739–746 (1989).
Finlay, C., Hinds, P.W. & Levine, A.J. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57, 1083–1093.
Harvey, M. et al. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet. 5, 225–229 (1993).
Jacks, T. et al. Tumour spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1–7 (1994).
Purdie, C. et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9, 603–609 (1994).
Fearon, E. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 759–767 (1990).
Kemp, C.J., Wheldon, T. & Balmain, A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet. 8, 66–69 (1994).
Ory, K., Legros, Y., Auguin, C. & Soussi, T. Analysis of the most representative tumour-derived p53 mutants reveals that changes In protein conformation are not correlated with loss of transactivation or Inhibition of cell proliferation. EMBO J. 13, 3496–3504 (1994).
Prosser, J., Thompson, A.M., Cranston, G. & Evans, H.J. Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene 5, 1573–1579 (1990).
Li, B. et al. Preferential overexpression of a 172Arg-Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development. Cell Growth Diff. 5, 711–721 (1994).
Sehgal, P.B. & Margulies, L. Cell type and promoter dependent phenotype of p53 Val 135. Oncogene 8, 3417–3419 (1993).
Reed, K.C. & Mann, D.A. Rapid transfer of DNA from agarose gels to nylon membranes. Nucleic Acids Res. 13, 7207–7221 (1985).
Harvey, M. et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deflclent mice. Oncogene 8, 2457–2467 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harvey, M., Vogel, H., Morris, D. et al. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53–deficient mice. Nat Genet 9, 305–311 (1995). https://doi.org/10.1038/ng0395-305
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0395-305
This article is cited by
-
Dominant-negative p53-overexpression in skeletal muscle induces cell death and fiber atrophy in rats
Cell Death & Disease (2022)
-
Attenuation of p53 mutant as an approach for treatment Her2-positive cancer
Cell Death Discovery (2020)
-
Analysis across multiple tumor types provides no evidence that mutant p53 exerts dominant negative activity
npj Precision Oncology (2019)
-
Mutational processes shape the landscape of TP53 mutations in human cancer
Nature Genetics (2018)
-
p53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation
Oncogene (2014)